Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25920777 | 1.00 | TRPV1 (0.37) | TRPV1RBP4PRMT5WDR77NPC1 | |
| SCHEMBL25324948 | 1.00 | TRPV1 (0.37) | TRPV1RBP4PRMT5WDR77NPC1 | |
| SCHEMBL30551504 | 0.96 | TRPV1 (0.36) | TRPV1RBP4PRMT5WDR77 | |
| SCHEMBL25323291 | 0.96 | TRPV1 (0.36) | TRPV1RBP4PRMT5WDR77 | |
| SCHEMBL25324708 | 0.82 | KDM1A (0.39) | PRMT5WDR77 | |
| SCHEMBL25920778 | 0.81 | TRPV1 (0.39) | TRPV1PRMT5WDR77NPC1RAB9A | |
| SCHEMBL25322685 | 0.81 | TRPV1 (0.39) | TRPV1PRMT5WDR77NPC1RAB9A | |
| SCHEMBL25322681 | 0.81 | TRPV1 (0.39) | TRPV1PRMT5WDR77NPC1RAB9A | |
| SCHEMBL25319439 | 0.79 | PRMT5 (0.36) | PRMT5WDR77HCRTR1HCRTR2 | |
| SCHEMBL25323259 | 0.79 | PRMT5 (0.36) | PRMT5WDR77HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | TRPV1 3504/4885RBP4 2574/4885PRMT5 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.